Hematology
Hemophilia A: the approved drugs compared for prescribers
Altuviiio, Hemlibra side by side on what each first fill waits on, what the label requires you to monitor and what an insurer asks to see, with FDA decisions, label changes and open trials for hemophilia A.
The 2 hemophilia A prescribing guides
One page per drug with the dispensing gate, prior authorization documentation, dosing, monitoring and interactions, each line sourced.
The drugs side by side
Each cell is a summary of that drug's prescribing guide, which carries the full detail and a source on every line. Insurer thresholds are one public policy shown as an example; plans differ.
| Altuviiioantihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl (efanesoctocog alfa) | Hemlibraemicizumab-kxwh | |
|---|---|---|
| Label dated | October 20, 2026 | July 11, 2025 |
| Starting dose | 50IU/kg IV once weekly, adults and children. No pediatric dose adjustment. | Loading dose 3mg/kg subcutaneously once weekly. Mean trough at week 5 was 52.6 ± 13.6 µg/mL. |
| Dispensing gate | No REMS and no boxed warning; prior authorization, HemAssist enrollment online or by fax, specialty pharmacy shipment and IV infusion training before the first home dose | No REMS; specialty pharmacy, treatment center or hospital pharmacy dispensing after prior authorization; HEMLIBRA Access Solutions starts only once both the Prescriber Service Form and the Patient Consent Form are received |
| Required monitoring | Clinical and laboratory monitoring for FVIII inhibitors; measure FVIII activity with a one-stage clotting assay (chromogenic overestimates about 2.5-fold); watch for hypersensitivity | No scheduled lab monitoring in the label; do not use aPTT-based assays to monitor Hemlibra, dose factor or measure inhibitors; watch for TMA and thrombosis if aPCC is given and for loss of efficacy from neutralizing antibodies |
| Example PA threshold | Cigna example: hemophilia specialist; FVIII inhibitor test within 30 days under 1.0BU/mL or no prior FVIII; prophylaxis up to 50IU/kg no more than weekly; 1-year approvals | Cigna example: documented hemophilia A with or without inhibitors, routine prophylaxis, hemophilia specialist, prophylactic bypassing agents stopped or prophylactic FVIII stopped within 4 weeks, no ITI with inhibitors, no concurrent Alhemo, Hympavzi or Qfitlia |
| Support line | Sanofi HemAssist, 1-833-723-5463, Monday to Friday 8 AM to 7 PM ET, fax 1-855-398-7634; commercial copay as little as $0; Free Trial first 30-day supply; Patient Assistance Program | HEMLIBRA Access Solutions, 877-233-3981, Case Managers and Field Reimbursement Managers for benefits checks, PA and appeal resources; copay as little as $0 with up to $15,000 a year for commercial plans at (844) 436-2672; Genentech Patient Foundation at (888) 941-3331 |
- Label dated
- October 20, 2026
- Starting dose
- 50IU/kg IV once weekly, adults and children. No pediatric dose adjustment.
- Dispensing gate
- No REMS and no boxed warning; prior authorization, HemAssist enrollment online or by fax, specialty pharmacy shipment and IV infusion training before the first home dose
- Required monitoring
- Clinical and laboratory monitoring for FVIII inhibitors; measure FVIII activity with a one-stage clotting assay (chromogenic overestimates about 2.5-fold); watch for hypersensitivity
- Example PA threshold
- Cigna example: hemophilia specialist; FVIII inhibitor test within 30 days under 1.0BU/mL or no prior FVIII; prophylaxis up to 50IU/kg no more than weekly; 1-year approvals
- Support line
- Sanofi HemAssist, 1-833-723-5463, Monday to Friday 8 AM to 7 PM ET, fax 1-855-398-7634; commercial copay as little as $0; Free Trial first 30-day supply; Patient Assistance Program
- Label dated
- July 11, 2025
- Starting dose
- Loading dose 3mg/kg subcutaneously once weekly. Mean trough at week 5 was 52.6 ± 13.6 µg/mL.
- Dispensing gate
- No REMS; specialty pharmacy, treatment center or hospital pharmacy dispensing after prior authorization; HEMLIBRA Access Solutions starts only once both the Prescriber Service Form and the Patient Consent Form are received
- Required monitoring
- No scheduled lab monitoring in the label; do not use aPTT-based assays to monitor Hemlibra, dose factor or measure inhibitors; watch for TMA and thrombosis if aPCC is given and for loss of efficacy from neutralizing antibodies
- Example PA threshold
- Cigna example: documented hemophilia A with or without inhibitors, routine prophylaxis, hemophilia specialist, prophylactic bypassing agents stopped or prophylactic FVIII stopped within 4 weeks, no ITI with inhibitors, no concurrent Alhemo, Hympavzi or Qfitlia
- Support line
- HEMLIBRA Access Solutions, 877-233-3981, Case Managers and Field Reimbursement Managers for benefits checks, PA and appeal resources; copay as little as $0 with up to $15,000 a year for commercial plans at (844) 436-2672; Genentech Patient Foundation at (888) 941-3331
FDA decisions for hemophilia A
From the Trial Friend FDA decision calendar, which records each date from the sponsor's or the FDA's own announcement.
- Date not disclosedDenecimig (Mim8), BLA, Novo NordiskReview extended
Recent label changes
What changed in each label revision, from the FDA's approval letters and the labels' own revision lists.
- December 2025Altuviiio. The FDA approved new warning and side effect text on December 29th, based on reports of inhibitors since approval. FDA letter
- July 2025Hemlibra. The FDA approved adding hypersensitivity to the list of side effects reported since approval, on July 8th. FDA letter
- March 2025Altuviiio. The allergic reaction warning and the list of side effects reported since approval were updated on March 7th. FDA letter
- May 2024Altuviiio. Results from the completed study in children under 12 were added to the label on May 10th. FDA letter
- January 2024Hemlibra. A new 12mg vial was added to support use in newborns and reduce wasted medicine. The immunogenicity sections were also updated. FDA letter
- February 2023Altuviiio. The FDA first approved Altuviiio on February 22nd for adults and children with hemophilia A. FDA letter
- June 2022Hemlibra. Rash, hives and angioedema were added as side effects reported since approval. FDA letter
- December 2021Hemlibra. The warnings, side effects, counseling and Medication Guide were updated with new data on antibodies against Hemlibra. FDA letter
Open trials
Questions prescribers ask about Hemophilia A
Which Hemophilia A drugs require a REMS?
None of the 2 Hemophilia A drugs on this page has a REMS: Altuviiio and Hemlibra. Each prescribing guide lists what does gate the first fill.
What monitoring do Hemophilia A drugs require?
Altuviiio: Clinical and laboratory monitoring for FVIII inhibitors; measure FVIII activity with a one-stage clotting assay (chromogenic overestimates about 2.5-fold); watch for hypersensitivity. Hemlibra: No scheduled lab monitoring in the label; do not use aPTT-based assays to monitor Hemlibra, dose factor or measure inhibitors; watch for TMA and thrombosis if aPCC is given and for loss of efficacy from neutralizing antibodies.
What do insurers require before covering Altuviiio and Hemlibra?
Each answer below is one public insurer policy, an example rather than every plan. Altuviiio: Cigna example: hemophilia specialist; FVIII inhibitor test within 30 days under 1.0BU/mL or no prior FVIII; prophylaxis up to 50IU/kg no more than weekly; 1-year approvals. Hemlibra: Cigna example: documented hemophilia A with or without inhibitors, routine prophylaxis, hemophilia specialist, prophylactic bypassing agents stopped or prophylactic FVIII stopped within 4 weeks, no ITI with inhibitors, no concurrent Alhemo, Hympavzi or Qfitlia.
Which support programs start Hemophilia A patients on therapy?
Altuviiio: Sanofi HemAssist, 1-833-723-5463, Monday to Friday 8 AM to 7 PM ET, fax 1-855-398-7634; commercial copay as little as $0; Free Trial first 30-day supply; Patient Assistance Program. Hemlibra: HEMLIBRA Access Solutions, 877-233-3981, Case Managers and Field Reimbursement Managers for benefits checks, PA and appeal resources; copay as little as $0 with up to $15,000 a year for commercial plans at (844) 436-2672; Genentech Patient Foundation at (888) 941-3331.
A reference for licensed professionals, checked on November 8, 2026. Labels and plan policies change; the label on DailyMed and the plan's current policy govern. Not medical advice. For patients: the Hemophilia A page and the first 90 days pages for Altuviiio, Hemlibra.